Enliven Therapeutics (NASDAQ:ELVN) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.07, Zacks reports. The business had revenue of $0.03 million during the quarter.

Enliven Therapeutics Stock Performance

NASDAQ:ELVN traded up $0.30 during trading hours on Monday, hitting $21.04. 140,000 shares of the company's stock traded hands, compared to its average volume of 269,605. Enliven Therapeutics has a twelve month low of $11.67 and a twelve month high of $30.03. The firm has a market cap of $1.03 billion, a P/E ratio of -11.07 and a beta of 1.04. The stock's fifty day moving average price is $21.59 and its two-hundred day moving average price is $23.82.

Insider Buying and Selling at Enliven Therapeutics

In other news, CFO Benjamin Hohl sold 1,000 shares of the company's stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $25.04, for a total value of $25,040.00. Following the transaction, the chief financial officer now directly owns 13,000 shares of the company's stock, valued at approximately $325,520. This represents a 7.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Anish Patel sold 6,667 shares of the firm's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $21.93, for a total value of $146,207.31. Following the sale, the chief operating officer now directly owns 329,977 shares of the company's stock, valued at $7,236,395.61. This trade represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,784 shares of company stock valued at $1,092,375 in the last 90 days. 29.20% of the stock is currently owned by corporate insiders.

Remove Ads

Analyst Ratings Changes

Separately, BTIG Research initiated coverage on Enliven Therapeutics in a research report on Friday, December 13th. They set a "buy" rating and a $42.00 target price on the stock. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $38.25.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.